# Regulation of Immune Responses by the Activating and Inhibitory Myeloid-Associate Immunoglobuline-Like Receptors (MAIR) (CD300)

Akira Shibuya\*, Chigusa Nakahashi-Oda and Satoko Tahara-Hanaoka

Department of Immunology, Institute of Basic Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki 305-8575, Japan

Activating and inhibitory cell surface receptors play important roles in regulation of immune responses. Recent progress has demonstrated that many inhibitory receptors pair with activating, as well as inhibitory, isoforms, both of whose genes are located in small clusters on a chromosome. We and others identified paired activating and inhibitory immunoglobulin-like receptors, designated myeloid-associated immunoglobulin-like receptors (MAIR) (CD300). MAIR is a multigene family consisting of nine genes on a small segment of mouse chromosome 11. MAIR family receptors are preferentially expressed on myeloid cells, including macrophages, dendritic cells, granulocytes, and bone-marrow-derived cultured mast cells, and a subset of B cells and regulate activation of these cells. Thus, MAIR plays an important role in innate immunity mediated by myeloid cells.

[Immune Network 2009;9(2):41-45]

### INTRODUCTION

Activating and inhibitory cell surface receptors play important roles in regulation of immune responses (1,2). The immune inhibitory receptors contain immunoreceptor tyrosine-based inhibitory motif (ITIM) in their cytoplasmic domains. The prototype 6-amino acid sequence for ITIM is (I/V/L/S)-x-Y-x-x-(L/V) (x denotes any amino acid), whose tyrosine is phosphorylated upon ligand binding, providing a docking site for the recruitment of Src homology 2 (SH2)-containing cytoplasmic phosphatases (3,4) and shutting down activation signals by dephosphorylation of intracellular substrates at the earliest

steps of the activation response.

In contrast, the activating receptors have a short cytoplasmic domain and contain a charged amino acid residue in the transmembrane region, which is involved in association with immunoreceptor tyrosine-based activating motif (ITAM)-bearing adaptor transmembrane proteins, such as Fc RI or DAP12, or with DAP10 adaptor containing PI3 kinase binding motif (5,6). These adapter proteins are tyrosine phosphorylated by the src family protein tyrosine kinases (PTKs) Syk or Zap70 upon ligand binding, resulting in activation of down stream signaling molecules in lymphoid and myeloid cells. Recent progress has demonstrated that many inhibitory receptors pair with activating, as well as inhibitory, isoforms (2,7), both of whose genes are located in small clusters on a chromosome (8).

Myeloid cells, including neutrophils and macrophages, play an essential role for host defenses against infectious microbial pathogens (9). Myeloid cells are activated through a vast array of cell surface receptors, such as Fc receptors for IgG,  $\beta 2$  integrins, complement receptors, chemokines, cytokine receptors and Toll-like receptors, and mediate phagocytosis, degranulation of anti-microbial substances or secretion of inflammatory mediators. However, how activation of myeloid cells is regulated is incompletely understood. We and others identified and characterized paired activating and inhibitory immunoglobulin-like receptors, designated myeloid-associated immunoglobulin-like receptors (MAIR)-I and MAIR-II and MAIR-IV and MAIR-V, whose extracellular domains are highly conserved with each other, respectively. In this review, we describe molecular and functional characteristics of the MAIR

Received on March 23, 2009. Accepted on March 31, 2009.

\*Corresponding Author. Tel: 81-29-853-3474; Fax: 81-29-853-3410; E-mail: ashibuya@md.tsukuba.ac.jp

Keywords: MAIR, CD300, activating receptor, inhibitory receptor

### IDENTIFICATION OF THE MAIR

To identify novel genes encoding cell surface receptors involved in immune responses by myeloid cells, we performed representative differential analysis (RDA) which is a PCRbased subtractive hybridization, using day 14 fetal livers from PU\_1-/-mice lacking myeloid cells and control littermates. Among several cDNA clones unique to myeloid cells identified, we found a novel gene encoding a member of the Ig superfamily, designated MAIR-I. The cytoplasmic domain of MIAR-I contains the ITIM-like sequences (VEY<sup>258</sup>STL and LHY<sup>270</sup>SSV, respectively) based on the consensus sequence for ITIMs (I/V/L/SxYxxL/V) (Fig. 1), suggesting that MAIR-I may recruit protein tyrosine phosphatases and mediates inhibitory signals. We also identified a clone encoding the protein, designated MAIR-II, which contains one Ig-like domain with 92% amino acid identity to that of MAIR-I in extracellular domain, a transmembrane region with a charged aa (Lys) and a short (20 aa) cytoplasmic tail (Fig. 1). The MAIR-I and MAIR-II genes are located to the proximal region of E2 band of mouse chromosome 11. MAIR-I and MAIR-II are also named as CLM8/LMIR1 and CLM4/LMIR2/DIgR1, respectively (10-12)

By screening a database for the mouse genome, we and others found that MAIR-I and MAIR-II are members of a multigene family consisting of nine genes on a small segment of mouse chromosome 11 (11,13) (Fig. 2).

We cloned all the full-length cDNAs of the MAIR family genes other than MAIR-I and MAIR-II by PCR from the spleen of C57BL/6 mice and designated them as MAIR-III to MAIR-IX, based on a phylogenetic tree analysis (Fig. 3). We found that one of the genes, MAIR-IV, has a short cytoplasmic tail (24 aa) with no signaling motif and a negatively charged glutamic acid (E) in its transmembrane (TM) region (Fig. 1). The Ig-like domain of MAIR-IV in the extracellular portion has 91% identity with that of MAIR-V at the amino acid level. In





Figure 1. Molecular characteristics of MAIR. MAIR family receptors belong to immunoglobulin superfamily with one immunoglobulin domain in the extracel-Iular portion. MAIR-I and MAIR-II and MAIR-V and MAIR-IV are paired inhibitory and activating receptors, respectively, with high homology in the extracellular portion each other. MAIR-I and MAIR-V contain immunoreceptor tyrosine-based inhibitory motif (ITIM) in their cytoplasmic domains and mediate inhibitory signals. MAIR-II and MAIR-IV associates immunoreceptor tyrosine-based activating motif (ITAM)-bearing adaptor transmembrane proteins Fc RI or DAP12 and mediate activation signals.

### Mouse Ch 11E2



### Human Ch 17q25.1



Figure 2. Gene localization of MAIR family. Mouse and human MAIR family genes are mapped on chromosome 11 and 17, respectively.




Figure 3. Molecular phylogenetic tree of MAIR gene family. Phylogenetic analysis of the MAIR family genes was performed by using the UPGMA method of GENETYX-MAC software (Software develoment, Tokyo, Japan). MAIR-II, MAIR-III, MAIR-VII and MAIR-VIII contained a charged amino acid in the transmembrane portion, and some of them associate with ITAM-bearing adaptor. MAIR-I and MAIR-V contains ITIM in the cytoplasmic portion.

contrast to MAIR-IV, MAIR-V has a long cytoplasmic tail containing two consensus immunoreceptor tyrosine-based inhibitory motif (ITIM), suggesting that MAIR-IV and MAIR-V constitute paired activating and inhibitory receptors (Fig. 1). MAIR-IV and MAIR-V were also named as CLM5 and CLM1/DIgR2 (11,14,15), respectively. The MAIR family was found to be a murine counterpart of the human CMRF-35 (CD300) family (16-18), which is located on human chromosome 17, syntenic region of mouse chromosome 11 (Fig. 2).

## EXPRESSION AND FUNCTION OF MAIR-I AND MAIR-II, PAIRED INHIBITORY AND ACTIVATING RECEPTORS, RESPECTIVELY

MAIR-I is expressed on the majority of myeloid cells, including macrophages, dendritic cells, granulocytes, and bone-marrow-derived cultured mast cells, and a subset of B cells, but neither on T nor NK cells (19). In contrast, MAIR-II protein is detected only on cell surface of subsets of B cells and peritoneal macrophages (19,20).

MAIR-I contains the ITIM sequences in the cytoplasmic domain and inhibits IgE-mediated degranulation from mast cells (19). Analyses by using the transfectant of rat basophil leukemia RBI-2H3 expressing wild type or variable mutant MAIR-I at Y<sup>233</sup>, Y<sup>258</sup>, Y<sup>270</sup> and/or Y<sup>299</sup> demonstrated that both Y<sup>258</sup> and Y<sup>270</sup>, but not Y<sup>233</sup> and Y<sup>299</sup>, were phosphorylated and recruits SHP-1and SHIP upon cross-linking of MAIR-I, which were essentially required for inhibition of IgE-mediated degranulation from the RBI-2H3 transfectant (21).

MAIR-II associates with the immunoreceptor tyrosine-based activation motif-bearing adaptor DAP12 and stimulates pro-inflammatory cytokines and chemokine secretions from peritoneal macrophages (19). However, we found that cross-linking MAIR-II with monoclonal antibody induced secretion of significant amount of the inflammatory cytokines TNF- $\alpha$  and IL-6 from DAP12-/- as well as wild type peritoneal macrophages. Further studies demonstrated that MAIR-II associates with not only DAP12 but also FcR $\gamma$  chain homodimers in peritoneal macrophages (20). These findings present the first case of an activating receptor that uses either DAP12 or FcR $\gamma$ 

chain as a signaling adapter.

## EXPRESSION AND FUNCTION OF MAIR-IV AND MAIR-V, PAIRED ACTIVATING AND INHIBITORY RECEPTORS, RESPECTIVELY

MAIR-IV was preferentially expressed on Gr-1 high/Mac-1 + neutrophils from the peripheral blood, bone marrow, peritoneal cavity and spleen. MAIR-IV was also expressed on Mac-1<sup>+</sup>/Gr-1<sup>-</sup> macrophages from the spleen and bone marrow and CD11c<sup>+</sup> dendritic cells (DC), but not on T, B, NK cells or bone marrow-derived cultured mast cells (13). MAIR-IV contains a short cytoplasmic tail with no signaling motif, suggesting that MAIR-IV, like MAIR-II, mediates activating signals via ITAM-containing adapter proteins, such as FcR- $\gamma$  chain or DAP12. DAP12 associates with several activating NK receptors and myeloid cell-specific receptors, including human and mouse TREM-1, TREM-2, MDL-1, and PILR $\beta$ , SIRP  $\beta$ 1, mouse TREM-3 and CD200R3, CD200R4 and mouse MAIR-II, all of which contain a positively charged amino acid, such as lysine (K) or arginine (R), in their TM region (22). In contrast, FcR $\gamma$  chain is also able to associate with receptors, such as Fc $\gamma$ RIIIA and Fc $\varepsilon$ RI, which do not contain a positively charged amino acid in the TM region (23). Because MAIR-IV does not possess a positively charged amino acid in the TM region, FcR $\gamma$  chain might be a partner of MAIR-IV. In fact, MAIR-IV associate with FcR $\gamma$  chain in peritoneal macrophages as well as transfectants expressing MAIR-IV (13,14). Because MAIR-IV associates with FcR $\gamma$ chain, it may mediates an activating signal in neutrophils. Stimulation of MAIR-IV with plate-coated F(ab')<sub>2</sub> fragments of anti-MAIR-IV mAb induced TNF- $\alpha$  and IL-6 secretion from neutrophils or peritoneal exudatative cells, indicating that MAIR-IV is a novel activating receptor on neutrophils.

MAIR-V (CD300LF) was expressed on macrophages, but not on B cells, T cells or granulocytes, derived from the spleen and peritoneal cavity (24). Cross-linking MAIR-V with anti-MAIR-V monoclonal antibody induced cell death in peritoneal macrophages as well as in several transfectants expressing MAIR-V.

Scanning electron microscopy revealed loss of blebs from the surface of the dead cells mediated by MAIR-V, a morphological feature similar to that observed in apoptotic cells. However, further studies revealed that MAIR-V mediates caspase and ER stress-independent cell death by a novel mechanism,

### **CONCLUDING REMARKS**

MAIR family receptors are preferentially expressed on myeloid cells, including macrophages, dendritic cells, granulocytes, mast cells, and a subset of B cells and regulate activation of these cells. It is not clear at present how these activating and inhibitory receptors cooperate each other for regulation of immune responses by myeloid cells. To understand the role of MAIR family receptors in immune responses, it is essentially required to identify their ligands and characterize the receptor-ligand interaction *in vivo*.

### **ACKNOWLEDGEMENTS**

This research was supported in part by grants provided by the Ministry of Education, Science and Culture of Japan and the Program for Promotion of Fundamental Studies in Health Science of the National Institute of Biomedical Innovation (NIBIO). The authors have no conflicting financial interests.

### **CONFLICTS OF INTEREST**

The authors have no financial conflict of interest.

### **REFERENCES**

- 1. Ravetch JV, Lanier LL: Immune inhibitory receptors. Science 290;84-89, 2000
- Lanier LL: Face off-the interplay between activating and inhibitory immune receptors. Curr Opin Immunol 13;326-331, 2001
- Malbec O, Fong DC, Turner M, Tybulewicz VL, Cambier JC, Fridman WH, Daëron M: Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation, J Immunol 160;1647-1658, 1998
- Smith KM, Wu J, Bakker AB, Phillips JH, Lanier LL: Ly-49D and Ly-49H associate with mouse DAP12 and form activating receptors. J Immunol 161;7-10, 1998
- Lanier LL, Bakker AB: The ITAM-bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function. Immunol Today 21;611-614, 2000
- Love PE, Shores EW: ITAM multiplicity and thymocyte selection: how low can you go? Immunity 12;591-597, 2000
- Takai T, Ono M: Activating and inhibitory nature of the murine paired immunoglobulin-like receptor family. Immunol Rev 181;215-222, 2001
- 8. Martin AM, Kulski JK, Witt C, Pontarotti P, Christiansen FT: Leukocyte Ig-like receptor complex (LRC) in mice and men. Trends Immunol 23;81-88, 2002
- 9. Nathan C: Neutrophils and immunity: challenges and op-

- portunities. Nat Rev Immunol 6;173-182, 2006
- Kumagai H, Oki T, Tamitsu K, Feng SZ, Ono M, Nakajima H, Bao YC, Kawakami Y, Nagayoshi K, Copeland NG, Gilbert DJ, Jenkins NA, Kawakami T, Kitamura T: Identification and characterization of a new pair of immunoglobulin-like receptors LMIR1 and 2 derived from murine bone marrow-derived mast cells. Biochem Biophys Res Commun 307;719-729, 2003
- Chung DH, Humphrey MB, Nakamura MC, Ginzinger DG, Seaman WE, Daws MR: CMRF-35-like molecule-1, a novel mouse myeloid receptor, can inhibit osteoclast formation. J Immunol 171;6541-6548, 2003
- Luo K, Zhang W, Sui L, Li N, Zhang M, Ma X, Zhang L, Cao X: DIgR1, a novel membrane receptor of the immunoglobulin gene superfamily, is preferentially expressed by antigen-presenting cells. Biochem Biophys Res Commun 287;35-41, 2001
- Nakano T, Tahara-Hanaoka S, Nakahashi C, Can I, Totsuka N, Honda S, Shibuya K, Shibuya A: Activation of neutrophils by a novel triggering immunoglobulin-like receptor MAIR-IV. Mol Immunol 45;289-294, 2008
- Fujimoto M, Takatsu H, Ohno H: CMRF-35-like molecule-5 constitutes novel paired receptors, with CMRF-35-like molecule-1, to transduce activation signal upon association with FcRgamma. Int Immunol 18;1499-1508, 2006
- Shi L, Luo K, Xia D, Chen T, Chen G, Jiang Y, Li N, Cao X: DIgR2, dendritic cell-derived immunoglobulin receptor 2, is one representative of a family of IgSF inhibitory receptors and mediates negative regulation of dendritic cell-nitiated antigen-specific T-cell responses. Blood 108;2678-2686, 2006
- 16. Cantoni C, Bottino C, Augugliaro R, Morelli L, Marcenaro E, Castriconi R, Vitale M, Pende D, Sivori S, Millo R, Biassoni R, Moretta L, Moretta A: Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells, Eur J Immunol 29;3148-3159, 1999

- Clark GJ, Green BJ, Hart DN: The CMRF-35H gene structure predicts for an independently expressed member of an ITIM/ITAM pair of molecules localized to human chromosome 17. Tissue Antigens 55;101-109, 2000
- Clark GJ, Cooper B, Fitzpatrick S, Green BJ, Hart DN: The gene encoding the immunoregulatory signaling molecule CMRF-35A localized to human chromosome 17 in close proximity to other members of the CMRF-35 family. Tissue Antigens 57;415-423, 2001
- Yotsumoto K, Okoshi Y, Shibuya K, Yamazaki S, Taharaanaoka S, Honda S, Osawa M, Kuroiwa A, Matsuda Y, Tenen DG, Iwama A, Nakauchi H, Shibuya A: Paired activating and inhibitory immunoglobulin-like receptors, MAIR-I and MAIR-II, regulate mast cell and macrophage activation. J Exp Med 198;223-233, 2003
- Nakahashi C, Tahara-Hanaoka S, Totsuka N, Okoshi Y, Takai T, Ohkohchi N, Honda S, Shibuya K, Shibuya A: Dual assemblies of an activating immune receptor, MAIR-II, with ITAM-bearing adapters DAP12 and FcRgamma chain on peritoneal macrophages. J Immunol 178;765-770, 2007
- Okoshi Y, Tahara-Hanaoka S, Nakahashi C, Honda S, Miyamoto A, Kojima H, Nagasawa T, Shibuya K, Shibuya A: Requirement of the tyrosines at residues 258 and 270 of MAIR-I in inhibitory effect on degranulation from basophilic leukemia RBL-2H3. Int Immunol 17;65-72, 2005
- 22. Takaki R, Watson SR, Lanier LL: DAP12: an adapter protein with dual functionality. Immunol Rev 214;118-129, 2006
- Kim MK, Huang ZY, Hwang PH, Jones BA, Sato N, Hunter S, Kim-Han TH, Worth RG, Indik ZK, Schreiber AD: Fcgamma receptor transmembrane domains: role in cell surface expression, gamma chain interaction, and phagocytosis. Blood 101;4479-4484, 2003
- Can I, Tahara-Hanaoka S, Hitomi K, Nakano T, Nakahashida C, Kurita N, Honda S, Shibuya K, Shibuya A: Caspase-independent cell death by CD300LF (MAIR-V), an inhibitory immunoglobulin-like receptor on myeloid cells. J Immunol 180;207-213, 2008